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ABSTRACT
Objective: Imatinib, a breakthrough oral molecular-targeted therapy, has
demonstrated durable responses and signiﬁcant survival advantage com-
pared with interferon-based treatment. This study compares imatinib with
interferon in newly diagnosed chronic-phase chronic myeloid leukemia
(CML-CP) patients from the Chinese public health-care system perspective
(CPHSP).
Methods: One-year cost responder and lifetime cost-utility analyses were
conducted, respectively. Complete cytogenetic response was used to deﬁne
a responder. Direct medical costs were included. Response rates as well as
survival estimates were obtained from published literature.
Results: The cost per responder for interferon was close to 20 times
higher than that for imatinib. The cost per additional responder was
RMB36,545. The incremental cost-effectiveness ratio (ICER) comparing
imatinib with interferon was RMB73,674 (95% conﬁdence interval
RMB67,712–RMB79,637) per quality-adjusted life-year.
Conclusion: In newly diagnosed CML-CP, the cost per responder for
patients treated with imatinib is much lower than that for patients treated
with interferon. In the cost-utility analysis, the ICER is below the cost-
effectiveness threshold recommended by the World Health Organization
for developing countries. Therefore, imatinib is more cost-effective than
interferon from the CPHSP.
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Introduction
Chronic myeloid leukemia (CML) is a rare disease, with an
estimated 4570 new cases diagnosed in 2007 in the United States,
among 44,240 new cases of leukemia projected overall [1]. CML
represents nearly 13% to 14% of leukemias, and an estimated
20% of leukemias in adults [2,3]. There is no published CML
incidence data for China yet. Some local data indicate that the
CML incidence for China may be much lower, less than 1 per
100,000 per year. The median age of disease onset is 67 years old,
however, CML occurs in all age groups. Clinically, CML
progresses through three distinct phases of increasing severity and
refractoriness to therapy, namely, chronic phase (CP), accelerated
phase (AP), and blast crisis (BC) [2]. The majority of patients
(90%) is diagnosed in the CP upon presentation of disease [4].
Phase duration and survival shorten as patients progress through
the AP and BC. Untreated CML progresses from a CP to a rapidly
fatal blast phase, generally over 3 to 5 years [5]. The blast phase is
often preceded by a transition period, AP.
Understanding the pathogenesis of the disease began with the
discovery of the Philadelphia (Ph) chromosome followed by
appreciation of its molecular counterpart, the BCR–ABL fusion
gene [5,6]. Recognition of the tyrosine kinase (TK) activity of the
BCR–ABL proteins led to the discovery of imatinib. The intro-
duction of imatinib has resulted in a revolutionary step in the
management of CML and a shift in paradigm for the manage-
ment of cancer in general [7].
Imatinib (Glivec, Novartis, Basel, Switzerland) is an oral TK
inhibitor indicated for the treatment of Ph chromosome-positive
CML in all phases. Imatinib has become the standard of care and
is recommended by the US National Comprehensive Cancer
Network as the ﬁrst-line therapy for newly diagnosed CML-CP
patients. Interferon or allogeneic stem cell transplantation should
no longer be considered as initial therapy for CML-CP [8].
Furthermore, imatinib was recommended to be the preferred
initial treatment by an international expert panel [7].
In China, imatinib is recommended as ﬁrst-line treatment in
CML-CP. Nevertheless, many patients were still treated with
interferon as ﬁrst-line treatment or went on to bone marrow
transplant (BMT) because both interferon and BMT are widely
reimbursable, whereas imatinib is only reimbursable in a limited
number of cities with high reimbursement barriers. This study
compares the cost-effectiveness between imatinib and interferon
from the Chinese public health-care system perspective (CPHSP).
We hope that the results could supplement Chinese payers in the
decision on which treatment should be reimbursed for CML-CP
patients.
A number of imatinib cost-effectiveness studies in CML have
been published for the United States [9] and UK [10] as well as
China [11]. Nevertheless, all studies were based on short-term
(less than 2 years) clinical data. Two recent publications using
imatinib 5-year follow-up data demonstrated that imatinib was
more cost-effective than interferon in treating CML-CP from the
US [12] and Brazil [13] payers’ perspective, respectively. This
study used the survival data from Reed et al. [12] to compare
imatinib with interferon from the CPHSP.
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Methods
Two cost-effectiveness analyses were conducted to compare ima-
tinib with interferon in newly diagnosed CML-CP patients. Inter-
feron monotherapy was used because in China, interferon is
usually used as a monotherapy. Newly diagnosed patients were
deﬁned as patients who were diagnosed with CML-CP and
have not been treated or have been minimally pretreated with
hydroxyurea.
Cost Responder
Complete cytogenetic response (CCyR) is associated with long-
term survival in CML and is an effective measure for treatment
efﬁcacy [14–18] (for details of References 14–26, see Cost-
Effectiveness Study Comparing Imatinib with Interferon-a for
Patients with Newly Diagnosed Chronic-Phase (CP) Chronic
Myeloid Leukemia (CML) from the Chinese Public Health-
Care System Perspective (CPHSP) Value in Health Supporting
Information, part VI at: http://www.ispor.org/Publications/
value/ViHsupplementary/ViH12s3_Feng.asp). Furthermore, the
European Leukemia Net (ELN) deﬁned CCyR at 12 months
after diagnosis as an optimal response [19]. If a patient achieved
a CCyR at 12 months, the patient is deﬁned as a responder;
otherwise, the patient is a nonresponder. This study did not
compare CCyR at 18 months because of the following reasons:
CCyR is not available for patients treated with interferon
monotherapy; and the CCyR from O’Brien’s [20] study was for
patients treated with interferon in combination with cytarabine.
The cost per responder at 12 months was calculated by dividing
the 12-month cost of treatment by the CCyR rate. The cost per
additional responder was calculated by dividing the difference in
costs (imatinib minus interferon) by the difference in response
rate. The 12-month cost of treatment consists of the direct
medical costs that occurred during the ﬁrst year of treatment:
drug cost, ofﬁce visits, and blood/lab tests. Hospitalization costs
were not included as few patients require hospitalization during
the CP [9]. Treatment costs to manage adverse events (AEs)
were not included as data were unavailable for China. Patients
treated with imatinib will incur signiﬁcantly less side effects
than those treated with interferon [20]. By excluding the treat-
ment costs managing AEs, we underestimated the cost savings
from AEs for imatinib.
Data
The CCyR at 12 months for imatinib was obtained from the
International Randomized Interferon versus STI571 (IRIS) study
[21], whereas the CCyR for interferon was from Baccarani et al.
[22]. No published data were available for imatinib CCyR for
China patients; therefore, we used the published IRIS data.
Regarding CCyR for interferon, the only published China data
showed that CCyR at 19 months for interferon used in combi-
nation with hydroxyurea and cytarabine was 3.2% [23]. The
CCyR for interferon from the IRIS study was not used because
that is for interferon combined with cytarabine. Additionally,
over half of the interferon arm patients crossed over to imatinib
after 19 months. Therefore, CCyR for interferon from Baccarani
et al. [22] was used. The patient populations from the IRIS and
Baccarani et al. [22] studies were similar, with both containing
newly diagnosed CML-CP patients who had not been treated or
had been minimally pretreated with hydroxyurea. Price informa-
tion on drugs was obtained from the listed retail price in China.
The price for interferon was based on imported interferon as the
qualities and prices for domestic-made interferon vary widely.
More importantly, to our knowledge, there is no publication on
treatment outcomes, such as cytogenetic response, for domestic-
made interferon. Unit costs on ofﬁce visit and blood test were
estimated based on the average fees charged by top tier hospitals
in China (Table S1). For more details, see Cost-Effectiveness
Study Comparing Imatinib with Interferon-a for Patients with
Newly Diagnosed Chronic-Phase (CP) Chronic Myeloid Leuke-
mia (CML) from the Chinese Public Health-Care System Perspec-





The framework of the lifetime cost-utility analysis is presented in
Figure S1 (for details, see Cost-Effectiveness Study Comparing
Imatinib with Interferon-a for Patients with Newly Diagnosed
Chronic-Phase (CP) Chronic Myeloid Leukemia (CML) from the
Chinese Public Health-Care System Perspective (CPHSP) Value in
Health Supporting Information, part I at: http://www.ispor.org/
Publications/value/ViHsupplementary/ViH12s3_Feng.asp). In
this analysis, CML-CP patients who received interferon ﬁrst,
imatinib will not be a treatment option. Similarly, with CML-CP
patients who received imatinib ﬁrst, interferon will not be a
treatment option. This will allow us to have a clean comparison
between imatinib and interferon. For patients who progressed
into advanced phases, we assigned the same time in AP and BC,
and the same utility weights and estimates of resource use for
both treatment groups. The time in each disease phase deter-
mines the life-years (LYs). The total LYs for both treatment
groups were obtained from Reed et al. [12]. Time in advanced
phases was assumed to be the same for both treatment groups,
with 10 months in AP and 13 months in BC phase [9]. Adjusting
the duration in each disease phase by the appropriate utility
weight determines the quality-adjusted LY (QALYs). Drug costs
as well as other treatment costs incurred during all disease phases
determine the total costs with each treatment choice (imatinib or
interferon). In the cost-utility analysis, the direct medical costs
for CP included the same resources as the costs in the cost
responder analysis, where hospitalizations and costs managing
AEs were not included. Nevertheless, the direct medical costs for
advanced phases included hospitalizations. Based on the total
cost and health outcomes, the incremental cost-effectiveness ratio
(ICER) can be computed.
Data
This study applied the lifetime survival data for imatinib and
interferon from Reed et al. [12]. The Reed et al. [12] study used
the 60-month data from the IRIS trial to extrapolate and estimate
the lifetime survival for imatinib. Because 58% of patients ran-
domized to receive interferon had crossed over to imatinib after
19 months [20], historical data from the literature were used to
estimate the lifetime survival for interferon [18,22]. In China, the
Global Imatinib Patient Assistance Program (GIPAP) has been
available since 2003, where many CML patients have been
treated with imatinib for 5 years. The 5-year survival was 91%
for CML patients receiving 400 mg/day in the GIPAP (data on
ﬁle), similar to the 5-year survival rate (89%) for CML-CP
patients treated with imatinib from the IRIS trial. Because this
GIPAP data are not published and there is no published lifetime
survival data for interferon in China, we used the published Reed
et al. [12] lifetime survival estimate for both imatinib and inter-
feron. Utility weights for CP and advanced phases were based on
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the Reed et al. [9] study, where utility weights were derived from
the EuroQol EQ-5D (a standardized instrument for use as a
measure of health outcome) collected in the IRIS trial.
Only direct medical costs were included. Treatment costs
were estimated based on treatment protocols from the top tier
hospitals in China. Unit price, administrative dose, as well as
frequency of resource use are presented in Table S1. All costs and
outcomes were discounted at a rate of 3.5% per annum follow-
ing the UK Health Technology Assessment recommendation in
the base-case scenario because there is no consensus on which
discount rate to use.
Results
Cost-Responder
In the base-case analysis, the dosage for interferon was 3 MIU
per day, reﬂecting the practice in China. Nevertheless, the CCyR
at 12 months for interferon was based on the interferon dosage
of 5 MIU per day from Baccarani et al. [22]. Therefore, a sensi-
tivity analysis was conducted for interferon 5 MIU per day. The
12-month cost of treatment associated with imatinib is 20%
higher than interferon; however, the CCyR rate for imatinib is 23
times better than that for interferon. Cost per responder for
interferon at 3 MIU per day is 19 times higher than that for
imatinib, whereas for interferon at 5 MIU per day, it is about 28
times higher than that for imatinib. The cost per additional
responder is RMB36,545, comparing imatinib with interferon
at 3 MIU per day. Imatinib dominates interferon at 5 MIU per
day in cost per additional responder (for details, see Cost-
Effectiveness Study Comparing Imatinib with Interferon-a for
Patients with Newly Diagnosed Chronic-Phase (CP) Chronic
Myeloid Leukemia (CML) from the Chinese Public Health-
Care System Perspective (CPHSP) Value in Health Supporting
Information, Part III at: http://www.ispor.org/Publications/value/
ViHsupplementary/ViH12s3_Feng.asp).
Cost-Utility
In the base-case analysis (for details, see Cost-Effectiveness Study
Comparing Imatinib with Interferon-a for Patients with Newly
Diagnosed Chronic-Phase (CP) Chronic Myeloid Leukemia
(CML) from the Chinese Public Health-Care System Perspective
(CPHSP) Value in Health Supporting Information, Part IV at:
http://www.ispor.org/Publications/value/ViHsupplementary/
ViH12s3_Feng.asp), patients receiving imatinib were estimated
to live an average of 19 years compared with 9 years for patients
receiving interferon, an incremental gain of 10 years. Adjusting
for quality of life, the incremental gain was 9.5 QALYs. Applying
a 3.5% discount rate, the incremental gain in survival was
6.3 years and 6.4 QALYs. Discounted lifetime costs were
RMB473,096 higher among patients receiving imatinib. Com-
bining the estimates in QALYs and lifetime costs, the ICERs were
RMB74,908 per LY saved and RMB73,674 per QALY. The
upper limits for both ICERs were around RMB80,000. Two
one-way sensitivity analyses were conducted (for details, see
Cost-Effectiveness Study Comparing Imatinib with Interferon-a
for Patients with Newly Diagnosed Chronic-Phase (CP) Chronic
Myeloid Leukemia (CML) from the Chinese Public Health-
Care System Perspective (CPHSP) Value in Health Supporting
Information, Part V at: http://www.ispor.org/Publications/value/
ViHsupplementary/ViH12s3_Feng.asp). The higher the discount
rate, the lower the ICER, hence, more favorable for imatinib.
Another sensitivity analysis was conducted for imatinib unit
price at the highest listed retail price (6% increase over the
base-case imatinib price) and the usual retail price (4% discount
of the base-case imatinib price). Both sensitivity analyses indicate
that the ICER is sensitive to the discount rate and the imatinib
price.
Conclusion and Discussion
The cost per responder for interferon is higher than that for
imatinib, and the cost per additional responder is RMB36,545.
Furthermore, the cost-utility analysis shows the ICERs of
RMB74,908 per LY gained and RMB73,679 per QALY compar-
ing favorably with the World Health Organization recommended
cost-effectiveness threshold as three times the GDP per capita for
developing countries [24,25].
Wang et al. [11] found the cost-effectiveness ratio to be
RMB156,000 per QALY, about twice as much compared with
this study. It used the IRIS study with 20-month follow-up,
whereas this study used Reed et al.’s [12] study where the IRIS
study with 60-month follow-up was used. Using 60 months
versus 20 months follow-up, imatinib demonstrated more sur-
vival advantage over interferon [12]. In addition, this study
incorporated the GIPAP scheme (the current practice in China) to
estimate the imatinib cost, which reﬂected about half of that used
in Wang et al. [11].
Some limitations of the study need to be considered. It is
assumed that is no price cut throughout the lifetime for imatinib
or interferon. In practice in China, once a product is listed on the
national reimbursement drug list, it faces a price cut every year in
the range of 2% to 10%. Therefore, we may have underesti-
mated the cost-effectiveness of imatinib. In both cost responder
and cost-utility analyses, treatment costs to manage AEs were not
included because in China, such data were difﬁcult to collect. We
expect that if we include the AE treatment costs, the results
would be more favorable for imatinib as patients treated with
imatinib require much less AEs management than those treated
with interferon [22]. Because of the durable responses and sur-
vival beneﬁt of imatinib, 86% of the patients treated with ima-
tinib in the IRIS study are alive after 7 years of follow-up [26].
Therefore, lifetime costs and survival for imatinib had to be
estimated and extrapolated based on available data. As longer
term data become available, it will be important to reevaluate the
cost-effectiveness if, by then, sufﬁcient mortality events become
available. In addition, this study used the published estimated
survival for imatinib and interferon, as patient-level data with
detailed clinical information were unavailable in China yet.
Imatinib has changed the natural history of CML by improv-
ing survival and transforming CML from a life-threatening to a
chronic disease. This breakthrough medicine is recommended
globally as the standard ﬁrst-line treatment [8,21]. Not only is it
effective, but also, it has been demonstrated to be cost-effective in
many jurisdictions [9–13]. This study conﬁrms that imatinib is
cost-effective than interferon-a from the CPHSP.
This study has been presented at the International Society for
Pharmacoeconomics and Outcomes Research (ISPOR) 3rd Asia-
Paciﬁc Conference and the Chinese Society for Pharmacoeco-
nomics and Outcomes Research inauguration, respectively, in
2008. Comments from the audience as well as from the four
reviewers are greatly appreciated.
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